Enlivex Therapeutics

The FDA has granted Allocetra from Enlivex RMAT designation for the treatment of symptomatic, age-related knee osteoarthritis in patients aged 64 and older. The designation is intended to enable faster and earlier engagement with the agency and may open accelerated review and approval pathways. Enlivex is currently running a randomized Phase IIb study with 182 patients in the US and Europe; the first US patient has already been treated and initial results are expected by the end of Q2 2027. The FDA has also requested a Type B meeting to discuss further development and approval planning; earlier Phase I/IIa data showed significant improvements versus placebo lasting at least six months. » More on de.investing.com

Enlivex has received a deficiency notice from NASDAQ because its common stock traded below the minimum requirement of $1.00 for 30 consecutive trading days. The stock is currently at $0.72; Enlivex has until November 9, 2026 (180 days) to regain compliance by having a closing bid of at least $1.00 for at least ten consecutive trading days. The company may request an additional 180-day grace period under certain conditions, for example if other listing requirements are met; otherwise a delisting process could follow. The notification has no immediate effect on the listing or trading. » More on de.investing.com

Enlivex has received approval from the Danish Medicines Agency to enroll patients in the global, multicenter phase‑2b study of Allocetra for moderate to severe age‑related primary knee osteoarthritis. The randomized, double‑blind, placebo‑controlled trial will evaluate the efficacy and safety of intra‑articular Allocetra injections at sites in the US, Denmark and Poland; the FDA had previously approved the US study. Key endpoints are changes in pain and function at three and six months after treatment, as well as quality of life and mobility. According to the company, Enlivex has a strong liquidity position and an exceptional current ratio; however, the stock shows high volatility with a beta of 1.68. » More on de.investing.com

Enlivex reported strong Q4/2025 financial results driven by substantial gains in its treasury holdings, notably the appreciation of the RAIN token, after which the stock rose about 15.8%. The company posted a net result of $1.23 billion, diluted EPS of $25.48, treasury holdings of $2.31 billion and equity of $1.93 billion. Enlivex received FDA approval for a Phase IIb study in osteoarthritis and expects top-line data in 2027; it also arranged $21 million in debt financing. Management highlights differentiation through prediction markets but warns of risks from clinical trials, crypto market volatility and regulatory hurdles. » More on de.investing.com

Enlivex sold 212 million common shares at USD 1.00 each, raising USD 212 million (funded in USD and USDT); at the same time, ex‑prime minister Matteo Renzi is being appointed to the board. The funds are intended, alongside the core business, for a treasury strategy involving the RAIN token, while development of Allocetra for the treatment of osteoarthritis continues. Despite high cash burn, Enlivex shows a strong short‑term liquidity position; H.C. Wainwright also maintains a buy rating with a USD 7 price target. » More on de.investing.com